 | | | | Related Healthscout Videos | |
|
THURSDAY, Jan. 4 (HealthDay News) -- Women who took Herceptin after surgery and chemotherapy for breast cancer had better survival odds after three years than women who didn't take the drug, a new study found.
The findings, published in the Jan. 6 issue of The Lancet, essentially validate previous research.
Text Continues Below
"This just confirms what we started doing at least a year ago," said Dr. Lauren Cassell, a breast surgeon at Lenox Hill Hospital in New York City. "It's validating what's become the standard of care here in the U.S."
Dr. Jay Brooks, chairman of hematology/oncology at Ochsner Health System in Baton Rouge, La., added, "This is very strong confirmation of the importance of identifying patients who would benefit from Herceptin."
An estimated 15 percent to 25 percent of breast cancers have abnormally high levels of the HER2/neu receptor and, as a result, are usually more aggressive. Herceptin (trastuzumab) blocks activity of the receptor by binding to the part of the receptor outside the cell. The drug has radically changed the prognosis for women with this type of breast cancer, especially when used in combination with chemotherapy. The drug is now standard therapy to reduce the risk of recurrence for those patients with HER2-positive metastatic breast cancer and is even being used for earlier-stage disease.
The new trial, conducted in London, is one of several large international studies designed to test Herceptin in women with HER2-positive early breast cancer.
In the Herceptin Adjuvant (HERA) study, researchers at Royal Marsden Hospital randomly selected 1,703 women to receive Herceptin for one year after surgery and chemotherapy, while another 1,698 women received no drug after surgery and chemotherapy. All the study participants had HER2-positive breast cancer and were followed for two years.
Page: 1 | 2 | Next >>
|
.gif)
